Menu

Physician Editorial

About Physician Editorial

http://physicianeditorial.com

Posts by Physician Editorial:

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

, , , ,

Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations March 30, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C […]

Merck Foundation Awards Grant to American Cancer Society for Program to Improve Access to High-Quality Cancer Care in Underserved Communities

, , , ,

$1.58 Million Grant Supports Patient Navigation Program, Empowering Patients and Caregivers with Information and Support March 24, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–The Merck Foundation (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation provided a grant of $1.58 million over four years to the ACS to implement a comprehensive Patient Navigation […]

Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

, , ,

In pivotal studies, most patients treated with Taltz achieved significant skin clearance (PASI 75, sPGA 0 or 1) with many achieving virtually clear (PASI 90) or completely clear (PASI 100, sPGA 0) skin at week 12 INDIANAPOLIS, March 22, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and […]

Steven Loranger Appointed To Edwards Lifesciences Board Of Directors

, ,

IRVINE, Calif., March 17, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Steven R. Loranger has been appointed to its board of directors. Loranger was most recently chief executive officer and president of leading global water technology company Xylem […]

WakeMed Among First in U.S. to Treat Heart Attack Patients with Supersaturated Oxygen in National Clinical Trial

Groundbreaking trial offers new intervention option, potential for improved outcomes for patients RALEIGH, N.C. (March 16, 2016) — WakeMed Health & Hospitals is the second hospital in the United States to treat a cardiac patient with a potentially breakthrough treatment that provides Supersaturated Oxygen (SSO2) Therapy to reduce damage to the heart muscle after a […]

Edwards Lifesciences Receives Approval For SAPIEN 3 Valve In Japan

, , , ,

IRVINE, Calif., March 16, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic […]

Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study

, , , ,

INDIANAPOLIS, March 15, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer’s dementia. The original study design included co-primary endpoints of cognition and function—measured by ADAS-Cog14 (Alzheimer’s Disease Assessment Scale-Cognitive subscale) […]

Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies

, ,

March 8, 2016 – KENILWORTH, N.J. & LYON, France–(BUSINESS WIRE)–Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their […]

Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept

, , ,

With ixekizumab, most patients who did not respond to treatment with etanercept in a Phase 3 clinical trial achieved virtually clear (Psoriasis Area Severity Index score [PASI] 90) or completely clear skin (PASI 100) after 12 weeks INDIANAPOLIS, March 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe […]

Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis: Results Published in JAMA Dermatology

, , ,

Results from the UNCOVER-1 study will also be presented at the American Academy of Dermatology (AAD) Annual Meeting, March 4-8, 2016, in Washington, D.C. INDIANAPOLIS, March 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect […]

«‹ 63 64 65 66›»